Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efsubaglutide alfa
- Development stage
- Phase 4
- Lead developer
- Innogen Pharma
- Modality
- Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Efsubaglutide alfa is a novel long-acting recombinant fusion protein that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. It is engineered by fusing GLP-1 with the Fc fragment of human IgG2, which significantly extends its half-life to approximately 204 hours. This design allows for once-weekly or biweekly subcutaneous dosing. The drug enhances glycemic control in type 2 diabetes by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying via activation of the GLP-1 receptor on pancreatic β-cells. Efsubaglutide alfa also demonstrates weight loss effects and potential cardiovascular benefits. It was first approved in China in January 2025 for adult type 2 diabetes and has shown efficacy in clinical trials for obesity and other metabolic disorders[2][6][10].
- Brand names
- Yinuoqing
- Other names
- supaglutideEfsubaglutide Alfa - Innogen Pharmaceutical TechnologySupaglutide injection - Shanghai Innogen Pharmaceutical Technology
02
Targets
Beyond the preview
Go deeper on efsubaglutide alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efsubaglutide alfa.